AbbVie snags priority review, breakthrough for HCV combo
This article was originally published in Scrip
Executive Summary
The FDA has granted a priority review to AbbVie's new drug application for its all-oral, interferon-free, two direct-acting antiviral (2-DAA) treatment regimen consisting of the fixed-dose combination of ombitasvir, paritaprevir and ritonavir (OBV/PTV/r) with ribavirin (RBV) as a treatment for adults with chronic genotype 4 hepatitis C virus (HCV).